# Korea United Pharm. Inc. clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Korea United Pharm. Inc. as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Korea United Pharm. Inc.: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/korea-united-pharm-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07935200 | Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults | Korea United Pharm. Inc. | Phase 1 | Not yet recruiting | Bioequivalence, Pharmacokinetics | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935200) |
| July 29, 2026 | NCT07735052 | Drug-drug Interaction Study Between UIC202304, and UIC202305 | Korea United Pharm. Inc. | Phase 1 | Completed | Healhty | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735052) |
| July 27, 2026 | NCT07727629 | Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers | Korea United Pharm. Inc. | Phase 1 | Not yet recruiting | Gastro Esophageal Reflux Disorder | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727629) |
| July 8, 2026 | NCT07691268 | Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions | Korea United Pharm. Inc. | Phase 1 | Completed | Dyslipidemia | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691268) |
| July 6, 2026 | NCT07682948 | A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and... | Korea United Pharm. Inc. | Phase 1 | Recruiting | Hypertension, Dyslipidemia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682948) |
| May 20, 2026 | NCT07600385 | A Study to Evaluate the Efficacy and Safety of UI022/UI023 | Korea United Pharm. Inc. | Phase 3 | Completed | Peripheral Arterial Disease | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07600385) |
| April 23, 2026 | NCT07548957 | A Study to Evaluate the Safety and Pharmacokinetics of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy... | Korea United Pharm. Inc. | Phase 1 | Not yet recruiting | Diabetes Mellitus (Type 2) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548957) |
| September 9, 2025 | NCT07162441 | A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of... | Korea United Pharm. Inc. | Phase 1 | Recruiting | Dyslipidemia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07162441) |
| August 8, 2025 | NCT07110740 | Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects | Korea United Pharm. Inc. | Phase 1 | Completed | Health | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07110740) |
| August 23, 2024 | NCT06568133 | Drug-drug Interaction Study Between UIC201603, and UIC201604 | Korea United Pharm. Inc. | Phase 1 | Completed | Healthy | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06568133) |
| May 1, 2024 | NCT06393881 | A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201 | Korea United Pharm. Inc. | Phase 1 | Unknown | Gastro-Intestinal Disorder | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06393881) |
| November 21, 2023 | NCT06141590 | A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions | Korea United Pharm. Inc. | Phase 1 | Completed | Diabetes Mellitus, Type 2 | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06141590) |
| November 21, 2023 | NCT06141577 | A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects | Korea United Pharm. Inc. | Phase 1 | Completed | GERD | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06141577) |
| March 16, 2022 | NCT05282914 | A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects | Korea United Pharm. Inc. | Phase 1 | Completed | GERD | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05282914) |
| January 13, 2022 | NCT05190133 | Drug-drug Interaction Study Between UIC201601 and UIC201602 | Korea United Pharm. Inc. | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05190133) |
| October 20, 2021 | NCT05085184 | Study to Evaluate the Safety and PK of UI018 | Korea United Pharm. Inc. | Phase 1 | Unknown | Hyperlipemia, Mixed | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05085184) |
| September 24, 2021 | NCT05055414 | Arformoterol/Budesonide for COVID-19 | Korea United Pharm. Inc. | Phase 2 | Unknown | Coronavirus Infection | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05055414) |
| December 11, 2020 | NCT04664803 | Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis | Korea United Pharm. Inc. | Phase 4 | Terminated | Acute Sinusitis | 284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04664803) |
| July 21, 2017 | NCT03225248 | Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia | Korea United Pharm. Inc. | Phase 3 | Completed | Functional Dyspepsia | 143 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03225248) |
| June 18, 2014 | NCT02166398 | A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and... | Korea United Pharm. Inc. | Phase 1 | Completed | Healthy | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02166398) |
| May 30, 2014 | NCT02151734 | Safety and Efficacy of KALOMIN™ Tab. in Patients With Acute Bronchitis | Korea United Pharm. Inc. | Phase 3 | Completed | Acute Bronchitis | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02151734) |
| April 26, 2013 | NCT01841086 | Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation | Korea United Pharm. Inc. | Phase 1 | Completed | Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01841086) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Not yet recruiting | 3 |
| Unknown | 3 |
| Recruiting | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dyslipidemias | 3 |
| Gastroesophageal Reflux | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Digestive System Diseases | 1 |
| Hyperlipoproteinemia Type V | 1 |
| Bronchitis | 1 |
| Peripheral Arterial Disease | 1 |
| Coronavirus Infections | 1 |
| Hypertension | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Scandinavian restaurants in the United States](https://specstream.ai/data/businesses/scandinavian-restaurants/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
- [Business brokers in the United States](https://specstream.ai/data/businesses/business-brokers/united-states)
- [Smoothie and juice bars in the United States](https://specstream.ai/data/businesses/smoothie-and-juice-bars/united-states)
- [Internet marketing agencies in the United States](https://specstream.ai/data/businesses/internet-marketing-agencies/united-states)
- [Carpet installation companies in the United States](https://specstream.ai/data/businesses/carpet-installation-companies/united-states)
